FDA Urges HCPs to Follow Authorized Dosing Schedules for COVID-19 Vaccines
Additional research from the vaccine manufacturers would be needed to support any changes to the dosing schedule.
Vaccine Information Center
Allergists Affirm Safety of COVID-19 Vaccines for Most
Researchers provide reassurance regarding potential allergic reactions to mRNA COVID-19 vaccinations from Pfizer and Moderna.
Top FDA Approvals of December 2020
In addition to 2 COVID-19 vaccines, the FDA approved multiple medications of import to nurse practitioners and physician assistants.
Pandemic-Related MMR Vaccine Decline Persists
There has been a 10% decline in young children receiving their first measles/mumps/rubella (MMR) vaccination by age 16 months.
ChAdOx1 nCoV-19 Vaccine Promising Against SARS-CoV-2 in Older Adults
AstraZeneca assessed the immunogenicity, safety, and efficacy of their novel chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1 nCoV-19.
Most US Adults Report That They Would Get COVID-19 Vaccine
Seventy-one percent of the US public report that they would get a COVID-19 vaccine, marking an increase from 63% in September.
High-Dose Trivalent Flu Shot No Better for Patients With CVD
For patients with high-risk CVD, high-dose trivalent inactivated influenza vaccination does not reduce cardiopulmonary hospitalization or all-cause mortality.
HPV Vaccine Generally Well Tolerated in Men
Human papillomavirus (HPV) vaccines are safe and well tolerated in male patients, with few reports of adverse events.
Flu Shot More Popular Than COVID-19 Vaccine Among Older Adults
Older adults are less likely to get a COVID-19 vaccine than a flu vaccine, according to the University of Michigan National Poll on Healthy Aging.
Standardizing Clinical Endpoints for COVID-19 Vaccine Efficacy Trials
To facilitate harmonized evaluation and comparison of the efficacy of COVID-19 vaccines, study authors proposed a general set of clinical endpoints, along with considerations to guide the selection of primary endpoints.
Influenza Vaccination Does Not Increase Risk for Guillain-Barré Syndrome
Study authors identified and evaluated a statistical signal for an increased risk of Guillain-Barré Syndrome in days 1-42 after 2018-2019 high-dose influenza vaccine administration.
Interventions to Increase HPV Vaccine Coverage Cost-Effective
Three interventions for increased human papillomavirus vaccine coverage are cost-effective.
As Rollout Nears, Small Practices and Rural Clinics Anticipate Challenges Storing and Administering COVID-19 Vaccines
The much-awaited remedy to the widespread transmission of SARS-CoV-2 comes with many logistical caveats.
Long-Term Immune Response With Single-Dose, Inactivated Japanese Encephalitis Vaccine
Study authors investigated the persistence of immune response with a single-dose of inactivated Japanese encephalitis vaccine and the interchangeability with a live-attenuated vaccine in healthy children aged 1 to 15 years.
Vaccine Candidate AZD1222 Effective Against COVID-19
A total of 131 cases of COVID-19 were reported in the interim analysis, with no hospitalizations or severe cases noted in participants who received the vaccine.
Interim Data Show COVID-19 Vaccine Candidate mRNA-1273 Near 95% Effective
The placebo-controlled COVE study is investigating the efficacy and safety of mRNA-1273 at the 100mcg dose (given intramuscularly in a 2-dose series, approximately 28 days apart) in more than 30,000 adults aged 18 years and older.
COVID-19 Vaccine Candidate More Than 90% Effective, Say Pfizer, BioNTech
The trial will continue as planned and final analysis is expected when the number of confirmed COVID-19 cases reaches 164.
Nurse Practitioners Prevent Spread of Diseases Among Homeless Population Through Vaccine Program
Nurse practitioners (NPs) executed a 5-step vaccination program for homeless individuals in Miami-Dade County to help reduce the spread of infectious diseases.
COVID-19 Vaccine Allocation: Ethical Concerns, Practical Challenges
In the event of a likely scarcity of COVID-19 vaccines, a framework must be developed to inform who should get priority.
2018 to 2019 Vaccine Cut Influenza A-Linked Hospitalizations
The 2018 to 2019 influenza vaccine effectiveness was about 40% to 60% for reducing pediatric influenza A-associated hospitalizations.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Vaccine Information Center
